Hemab Therapeutics (Nasdaq: COAG) presented clinical and preclinical data for its drug candidate sutacimig at the International Society on Thrombosis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE